Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426


PP-UNP-USA-5796

Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426


​​​​​​​PP-UNP-USA-5796

Order samples

Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.

 We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426


​​​​​​​PP-UNP-USA-5796

Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796

Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading

PP-UNP-USA-5796

Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Change IndicationLoading
Search
Menu
Close
PIAbout PANZYGAEfficacyEfficacyTrial designEfficacySafety and tolerabilityDosingPatient profilesMaterials and supportMaterials and supportEventsMaterialsVideosSupport homePANZYGA Co-Pay ProgramsPfizer IGuideFAQsRequest a representativeIg Companion
Prescribing InformationIndicationsPatient Site
PANZYGA Co-Pay ProgramsWith the PANZYGA Co-Pay Programs, eligible patients may pay as little as $0 What do the PANZYGA Co-Pay Programs provide?
Drug Co-Pay
  • The PANZYGA Co-Pay Program provides eligible, commercially insured patients assistance of up to $12,500 per calendar year or the cost of patient co-pay in a 12-month period, whichever is less. The PANZYGA Co-Pay Program is good only in the U.S. and Puerto Rico.
Admin Support Co-Pay
In addition, eligible patients may receive support to reduce out-of-pocket cost related to the administration of PANZYGA – including home infusions, administration services, and supplies/equipment
  • The value of Admin Co-Pay Support is limited to a maximum of $1,500 for PANZYGA per calendar year or the cost of patient co-pay in a 12-month period, whichever is less
No membership fees. Federal and state healthcare beneficiaries are not eligible. The PANZYGA Admin Co-Pay Support Program is not valid for Massachusetts or Rhode Island residents.
 Who is eligible?
  • Patients must be 2 years or older to be eligible
  • Patients must have commercial insurance to be eligible
  • Admin Support Co-Pay Program is not available for MA and RI residents
  • Patients are not eligible if they are enrolled in a state or federally funded insurance program
 How can a patient enroll?
  • Specialty infusion pharmacies may enroll eligible patients
  • Visit www.PfizerIGuide.comfor help with enrollment, financial assistance, and insurance support services
Terms and Conditions: By using the Panzyga Co-Pay Program you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:
  • Patients are not eligible to use the Panzyga Co-Pay Program card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs healthcare, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
  • Patient must have private insurance. Offer is not valid for cash-paying patients. The value of this co-pay card is limited to a maximum of $12,500 for Panzyga per calendar year or the cost of patient co-pay in a 12-month period, whichever is less. The value of the Admin Co-Pay Support is limited to a maximum of $1,500 for Panzyga per calendar year or the cost of patient co-pay in a 12-month period, whichever is less.
  • This co-pay card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
  • You must deduct the value of this co-pay card from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
  • You are responsible for reporting use of the co-pay card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer copay cards.
  • You must be 2 years of age or older to redeem the Panzyga Co-Pay Program Card.
  • This co-pay card is not valid where prohibited by law.
  • The benefit under the co-pay card program is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third party payers, pharmacy benefit managers, or the agents of either.
  • Co-pay card cannot be combined with any other external savings, free trial or similar offer for the specified prescription (including any program offered by a third party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator” or “maximizer” programs).
  • Third party payers, pharmacy benefit managers, or the agents of either, are prohibited from assisting patients with enrolling in the co-pay card program.
  • The Panzyga Co-Pay Program Card will be accepted only at participating pharmacies.
  • If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer.
  • This co-pay card is not health insurance.
  • The Panzyga Co-Pay Program is good only in the U.S. and Puerto Rico. The Panzyga Admin Co-pay Support Program is not valid for Massachusetts or Rhode Island residents.
  • The Panzyga Co-Pay Program Card are limited to 1 per person during this offering period and is not transferable.
  • Co-pay card may not be redeemed more than once per 13 days per patient for Panzyga.
  • No other purchase is necessary.
  • No membership fee.
  • Data related to your redemption of the co-pay card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you.
  • Pfizer reserves the right to rescind, revoke or amend this offer without notice.
  • Offer expires 12/31/2025.
For more information about the Panzyga Co-Pay Program call 1-866-293-5922. For more information about the Panzyga Co-Pay Program write: Panzyga Co-Pay Program, 
PO Box 6875, Bridgewater, NJ 08807.Materials and Support

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-PAN-USA-1049
You are now leaving Pfizer

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-MCL-USA-0367

INDICATIONS AND USAGE
PANZYGA (Immune Globulin Intravenous [Human] - ifas) is indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older; this includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies; chronic immune thrombocytopenia (cITP) in adults to raise platelet counts to control or prevent bleeding; and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults to improve neuromuscular disability and impairment.
IMPORTANT SAFETY INFORMATIONWARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE
  • Thrombosis may occur with immune globulin intravenous (IGIV) products, including PANZYGA. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
  • Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients who receive IGIV products, including PANZYGA. Patients predisposed to renal dysfunction include those with a degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. PANZYGA does not contain sucrose.
  • For patients at risk of thrombosis, renal dysfunction, or acute renal failure, administer PANZYGA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. [see Full Prescribing Information, Warnings and Precautions (5.2, 5.4)]
Contraindications
PANZYGA is contraindicated in patients who have a history of severe systemic hypersensitivity reactions, such as anaphylaxis, to human immunoglobulin and in IgA-deficient patients with antibodies against IgA and history of hypersensitivity.
Warnings and Precautions
Monitor renal function, including blood urea nitrogen and serum creatinine, and urine output in patients at risk of developing acute renal failure.
Hyperproteinemia, increased serum osmolarity, and hyponatremia may occur in patients receiving PANZYGA. 
Aseptic meningitis syndrome may occur in patients receiving PANZYGA, especially with high doses or rapid infusion.Hemolysis that is either intravascular or due to enhanced red blood cell sequestration can develop subsequent to PANZYGA treatments. Risk factors for hemolysis include high doses and non-O-blood group. Closely monitor patients for hemolysis and hemolytic anemia.Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]).Monitor blood pressure prior to, during, and following PANZYGA infusion.Carefully consider the relative risks and benefits before prescribing the high dose regimen (for cITP) in patients at increased risk of volume overload.PANZYGA is made from human plasma and may contain infectious agents, e.g. viruses and theoretically, the Creutzfeldt-Jakob disease agent.Adverse Reactions
PI – The most common adverse reactions (>5% study subjects) were headache, nausea, fever, fatigue, and abdominal pain.cITP in adults – The most common adverse reactions (>5% study subjects) were headache, fever, nausea, vomiting, dizziness, and anemia.CIDP in adults – The most common adverse reactions (>5% study subjects) were headache, fever, dermatitis, and blood pressure increase.The risk information provided here is not comprehensive; see full Prescribing Information and Boxed Warning for PANZYGA. You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088. PANZYGA® is a registered trademark of Octapharma AG. Please click here for full Prescribing Information, including BOXED WARNING.

Manufactured by Octapharma Pharmazeutika Produktionsges m.b.H.
Distributed by Pfizer Labs, Division of Pfizer Inc.
INDICATIONS
PANZYGA (Immune Globulin Intravenous [Human] - ifas) is indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older; this includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies; chronic immune thrombocytopenia (cITP) in adults to raise platelet counts to control or prevent bleeding; and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults to improve neuromuscular disability and impairment.